4.5 Review

Current and emerging strategies for management of myelodysplastic syndromes

Journal

BLOOD REVIEWS
Volume 48, Issue -, Pages -

Publisher

CHURCHILL LIVINGSTONE
DOI: 10.1016/j.blre.2020.100791

Keywords

MDS; HMA; Luspatercept; Roxadustat; Imetelstat; Guadecitabine; H3B-8800; APR-246; Venetoclax; Rigosertib; Checkpoint inhibitor; Magrolimab

Categories

Ask authors/readers for more resources

Myelodysplastic syndromes (MDS) are hematopoietic disorders characterized by ineffective blood cell production, with treatment strategies focusing on improving quality of life for lower-risk MDS and extending survival for higher-risk MDS. Several promising drugs are currently being investigated for MDS treatment.
Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis with varying degrees of dysplasia and peripheral cytopenias. MDS are driven by structural chromosomal alterations and somatic mutations in neoplastic myeloid cells, which are supported by a tumorigenic and a proinflammatory marrow microenvironment. Current treatment strategies for lower-risk MDS focus on improving quality of life and cytopenias, while prolonging survival and delaying disease progression is the focus for higher-risk MDS. Several promising drugs are in the horizon, including the hypoxia-inducible factor stabilizer roxadustat, telomerase inhibitor imetelstat, oral hypomethylating agents (CC-486), TP53 modulators (APR-246 and ALRN-6924), and the anti-CD47 antibody magrolimab. Targeted therapies approved for acute myeloid leukemia treatment, such as isocitrate dehdyrogenase inhibitors and venetoclax, are also being studied for use in MDS. In this review, we provide a brief overview of pathogenesis and current treatment strategies in MDS followed by a discussion of newer agents that are under clinical investigation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available